These four charts reveal a striking disconnect between NVIDIA’s long-term financial growth and its stock performance from 2001 to 2015. While revenue rose 249% and net income nearly doubled, the stock price declined slightly—demonstrating that price alone is not a reliable indicator of financial strength or future performance.
This report raises serious concerns about the alignment between Oracle’s current $650 billion market cap and its actual earnings performance and realistic future growth potential.
Equity Risk Sciences (ERS) announces its launch as America’s first independent Stock Risk Rating Agency. ERS provides quantitative, evidence-based ratings of the probability and magnitude of stock price changes.
By Raymond M. Mullaney May 28, 2025 [...]
The market cap of 9 of the 10 largest companies in America on 7/5/2024 was $18.26 trillion. The Fiduciary Risk Rating clearly indicated that most of these 9 companies were extremely risky.
Most of the investment industry still defines risk by volatility or beta—how much a stock’s price moves. But at Equity Risk Sciences (ERS), we believe that’s far too narrow. Risk is about the probability and magnitude of potential loss based on a company’s financial fundamentals, not its trading pattern.
Let’s walk through a fun little puzzle about investing in stocks—don’t worry, it’s not rocket science, and by the end, you’ll see how straightforward it can be. Imagine you’re buying a company for $300 billion, and right now, it’s bringing in $3 billion in revenue each year. Your goal? To double your money in five years, so the company’s market value hits $600 billion.
Investors often buy stocks based on emotions rather than facts. Apple (AAPL) offered two very different buying opportunities—one in December 1999 and another in December 2000. The key difference? Valuation.
Most people think investing is about picking stocks and hoping they go up. But real investing is more like running an insurance company. The most successful investors—those who have built billions in wealth—know that some of their investments will lose money. But they don’t let those losses shake their confidence because they understand the big picture.
Viking Therapeutics (VKTX) is a textbook example of how ERS risk ratings can help investors avoid catastrophic losses. Despite sharp declines in its stock price over the past year, VKTX remained a high-risk stock at every stage of its fall.